Cervical Cancer Management in the Modern Era: HPV Pathogenesis, Stage-Based Therapy, Immunotherapy, Antibody–Drug Conjugates, and Treatment Resistance—A Review

Review Article | DOI: https://doi.org/10.31579/2693-7247/253

Cervical Cancer Management in the Modern Era: HPV Pathogenesis, Stage-Based Therapy, Immunotherapy, Antibody–Drug Conjugates, and Treatment Resistance—A Review

  • Chinmyee Saha ID

PhD Scholar, School of Pharmacy, RK University, Rajkot, India.

*Corresponding Author: Chinmyee Saha, PhD Scholar, School of Pharmacy, RK University, Rajkot, India.

Citation: Chinmyee Saha, (2026), Cervical Cancer Management in the Modern Era: HPV Pathogenesis, Stage-Based Therapy, Immunotherapy, Antibody–Drug Conjugates, and Treatment Resistance—A Review, J. Pharmaceutics and Pharmacology Research, 9(2); DOI:10.31579/2693-7247/253

Copyright: © 2026, Chinmyee Saha. This is an open-access article distributed under the terms of the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original author and source are credited.

Received: 08 September 2026 | Accepted: 17 September 2026 | Published: 25 September 2026

Keywords: Cervical cancer; Human papillomavirus; HPV E6/E7; Chemotherapy; Immunotherapy; Targeted therapy; Treatment resistance; CRISPR-Cas9

Abstract

Cervical cancer remains a major global health problem and is primarily associated with persistent infection by high-risk human papillomavirus (HPV), particularly HPV-16 and HPV-18. Despite advances in HPV vaccination, screening, surgery, radiotherapy, chemotherapy, targeted therapy, and immunotherapy, cervical cancer continues to cause substantial morbidity and mortality, particularly in low- and middle-income countries. The molecular pathogenesis of cervical cancer involves HPV E6- and E7-mediated disruption of tumor-suppressor pathways, including p53 and retinoblastoma (Rb), together with dysregulation of PI3K/AKT/mTOR, MAPK/ERK, JAK/STAT, NF-κB, Wnt/β-catenin, TGF-β, VEGF, and PD-1/PD-L1 signalling. These molecular alterations promote uncontrolled proliferation, genomic instability, apoptosis resistance, angiogenesis, epithelial–mesenchymal transition, immune evasion, invasion, and metastasis. This review summarizes the current therapeutic landscape of cervical cancer according to disease stage, emphasizing conventional chemotherapy, anti-angiogenic therapy, immunotherapy, and emerging antibody–drug conjugates. Particular attention is given to cisplatin-based chemoradiation, bevacizumab, pembrolizumab, and the tissue factor-targeting antibody–drug conjugate tisotumab vedotin. Although these approaches have improved clinical outcomes, therapeutic resistance remains a major challenge. Mechanisms of resistance include enhanced DNA repair, drug efflux, apoptosis inhibition, cancer stem-cell persistence, impaired antigen presentation, T-cell exhaustion, alternative immune checkpoints, tumor heterogeneity, compensatory signaling, and an immunosuppressive tumor microenvironment. Understanding these mechanisms is essential for developing more effective therapeutic combinations. Finally, the review highlights emerging precision-medicine approaches, particularly CRISPR-Cas9-based gene editing. Targeting HPV E6/E7 and other genes associated with tumor survival, immune evasion, and treatment resistance may provide new opportunities for therapeutic intervention. Integrating molecular biomarkers with conventional and emerging therapies could facilitate personalized treatment strategies and improve durable disease control. Future research should prioritize rational combination therapies, predictive biomarkers, HPV-directed approaches, next-generation immunotherapies, antibody–drug conjugates, and gene-editing technologies to further reduce the global burden of cervical cancer.

1. Introduction

1.1 Global burden

Cervical cancer remains a major global public health challenge despite being largely preventable through human papillomavirus (HPV) vaccination, screening, early diagnosis, and effective treatment. According to WHO and IARC estimates, approximately 660,000 new cases and 350,000 deaths occurred worldwide in 2022. Nearly 90% of cervical cancer deaths occurred in low- and middle-income countries (LMICs), highlighting substantial global inequalities in vaccination, screening, diagnostic services, and access to cancer treatment [1–3]. Incidence and mortality vary considerably between regions, with particularly high burdens reported in sub-Saharan Africa, parts of Latin America and the Caribbean, South and Southeast Asia, and Melanesia [4,5]. Limited screening coverage, inadequate healthcare infrastructure, delayed diagnosis, and restricted access to radiotherapy and systemic therapies contribute substantially to this disparity [3,6].

Screening using HPV testing, cytology, and other validated approaches can markedly reduce cervical cancer incidence and mortality. However, screening coverage remains highly unequal worldwide. WHO has established the 90–70–90 elimination targets, aiming for 90% HPV vaccination among girls by age 15, 70% high-performance screening coverage by ages 35 and 45 years, and appropriate treatment for 90% of women with cervical precancer or invasive cancer [10,11].

1.2 Etiology

Persistent infection with high-risk HPV is the principal etiological factor in cervical carcinogenesis. HPV-16 and HPV-18 are the most clinically important oncogenic genotypes and together account for a substantial proportion of cervical cancers [12–16]. Although most HPV infections are transient and cleared by the immune system, persistent infection can lead to cervical intraepithelial neoplasia and invasive carcinoma. Viral E6 and E7 oncoproteins are central to malignant transformation. E6 promotes E6AP-mediated ubiquitination and degradation of the tumor suppressor p53, impairing DNA-damage responses and apoptosis, whereas E7 inactivates pRb, releases E2F transcription factors, and promotes uncontrolled G1/S cell-cycle progression [17–20].

1.3 Cervical cancer biology

Cervical carcinogenesis involves genomic instability, cell-cycle deregulation, apoptosis resistance, angiogenesis, epithelial–mesenchymal transition (EMT), immune evasion, and tumor-microenvironment interactions. HPV-mediated disruption of p53 and Rb pathways promotes abnormal proliferation and accumulation of genomic alterations. Increased VEGF signaling contributes to angiogenesis, while EMT-associated loss of E-cadherin and increased vimentin facilitate invasion and metastasis [21–25]. The tumor microenvironment, comprising immune cells, fibroblasts, endothelial cells, extracellular matrix, cytokines, and chemokines, further influences tumor progression and therapeutic response. Immune checkpoint pathways, particularly PD-1/PD-L1, contribute to immune escape [22].

1.4 Major histological types

The major histological forms include squamous cell carcinoma, adenocarcinoma, adenosquamous carcinoma, and neuroendocrine carcinoma.[26] Squamous cell carcinoma is the predominant subtype and is strongly associated with HPV-16, whereas adenocarcinoma is frequently associated with HPV-18 and HPV-16. Adenosquamous carcinoma contains both glandular and squamous components, while neuroendocrine carcinoma is rare but highly aggressive. Increasing recognition of HPV-associated and HPV-independent tumors and their molecular heterogeneity is important for biomarker discovery, prognosis, and development of precision therapeutic strategies [26].

2. Molecular Pathogenesis of Cervical Cancer

Cervical cancer develops through a multistep molecular process initiated predominantly by persistent infection with high-risk human papillomavirus (HPV), particularly HPV-16 and HPV-18. Persistent infection alone is insufficient for malignant transformation; progression involves viral genome integration, sustained expression of E6 and E7 oncoproteins, genomic instability, dysregulated signaling, angiogenesis, epithelial–mesenchymal transition (EMT), and immune evasion [26–29].

2.1 HPV E6/E7 and tumor-suppressor disruption

HPV E6 promotes E6AP-mediated ubiquitination and proteasomal degradation of p53, impairing DNA-damage responses, cell-cycle arrest, senescence, and apoptosis [26–29]. Conversely, HPV E7 binds and inactivates retinoblastoma protein (pRb), releasing E2F transcription factors and promoting inappropriate G1/S progression and DNA synthesis [30]. The combined effects of E6-mediated p53 suppression and E7-mediated Rb inactivation create a cellular environment favorable for genomic instability and malignant transformation. E7-associated Rb disruption also induces p16INK4a overexpression, making p16INK4a a useful surrogate marker of transforming HPV infection [31].

2.2 Major signaling pathways

Multiple interconnected pathways contribute to cervical cancer progression. Activation of the PI3K/AKT/mTOR and MAPK/ERK pathways promotes proliferation, survival, metabolism, migration, and therapeutic resistance, with alterations involving components such as PIK3CA and PTEN [32–34]. JAK/STAT, particularly STAT3, and NF-κB signaling promote proliferation, inflammation, angiogenesis, immune suppression, and survival [34–36]. Dysregulated Wnt/β-catenin and TGF-β signaling promotes stemness, EMT, invasion, and metastasis [37,38]. VEGF stimulates tumor angiogenesis, supporting tumor growth and dissemination [33,34].

2.3 Immune evasion and biomarkers

The PD-1/PD-L1 immune checkpoint pathway suppresses cytotoxic T-cell activity and facilitates immune escape, providing a biological basis for immune checkpoint blockade [34,35]. Important molecular biomarkers include HPV E6/E7, p53, Rb, p16INK4a, Ki-67, PD-L1, VEGF, EGFR, MDM2, and NFAT1, which reflect oncogenic signaling, proliferation, angiogenesis, immune regulation, and tumor progression.

Overall, cervical carcinogenesis results from extensive crosstalk among viral oncogenes, tumor-suppressor pathways, proliferative signaling, EMT, angiogenesis, and immune regulation. This molecular complexity supports biomarker-guided combination therapies and emerging targeted approaches, including CRISPR-Cas9-mediated disruption of HPV E6/E7.

3. Current Standard Treatment of Cervical Cancer

Treatment of cervical cancer is primarily determined by FIGO stage, tumor size, lymph-node status, histological characteristics, fertility considerations, previous therapy, and distant metastasis [39,40]. Current management has evolved from surgery and radiotherapy toward multimodal strategies incorporating chemotherapy, immunotherapy, anti-angiogenic therapy, and antibody–drug conjugates.

3.1 Early-Stage Cervical Cancer

Early-stage disease, particularly FIGO stage IA and selected IB–IIA tumors, is generally managed with surgery or radiation-based treatment [39–41]. Surgical options include conization, simple or radical hysterectomy, and trachelectomy, depending on tumor characteristics and fertility requirements. Conization may provide definitive treatment for carefully selected microinvasive disease, whereas radical hysterectomy with lymph-node assessment may be used for selected invasive tumors [40,41].

Sentinel lymph-node (SLN) evaluation is increasingly used in selected early-stage patients to detect nodal metastasis while potentially reducing  complications associated with complete lymphadenectomy [41,43]. Fertility-sparing procedures, including conization and trachelectomy, may be considered in appropriately selected women with small, localized tumors and no evidence of nodal or distant disease [41,43]. Patients with high-risk postoperative features, including positive lymph nodes, surgical margins, or parametrial involvement, generally require adjuvant chemoradiation [40,41].

3.2 Locally Advanced Cervical Cancer

For locally advanced disease, particularly FIGO stages IIB–IVA, the principal curative approach is concurrent chemoradiation followed by or incorporating brachytherapy [39,40]. External-beam radiotherapy (EBRT) targets the primary tumor and regional lymph nodes, while image-guided brachytherapy delivers a high radiation dose directly to the tumor. Cisplatin-based concurrent chemoradiation improves radiosensitivity and provides superior disease control compared with radiotherapy alone [40,45].

The treatment paradigm has recently expanded following KEYNOTE-A18, in which pembrolizumab combined with chemoradiotherapy improved progression-free survival, particularly in high-risk locally advanced disease [45].

3.3 Recurrent and Metastatic Disease

Recurrent or metastatic cervical cancer generally requires systemic therapy. Platinum–taxane combinations, particularly cisplatin/carboplatin plus paclitaxel, remain important chemotherapy regimens [39,40]. The GOG-240 trial established the benefit of adding bevacizumab, an anti-VEGF antibody, to chemotherapy [47,48].

The KEYNOTE-826 trial demonstrated improved survival with pembrolizumab plus chemotherapy ± bevacizumab, particularly in PD-L1-positive disease.[46] For previously treated recurrent/metastatic disease, tisotumab vedotin, an antibody–drug conjugate targeting tissue factor, provides another therapeutic option [49].

3.4 Conventional Chemotherapy and Limitations

Chemotherapeutic agents include cisplatin, carboplatin, paclitaxel, gemcitabine, irinotecan, topotecan, and ifosfamide [51]. Although chemotherapy remains clinically important, systemic toxicity, myelosuppression, nephrotoxicity, neuropathy, gastrointestinal effects, tumor heterogeneity, intrinsic or acquired chemoresistance, incomplete responses, and recurrence remain major limitations [51–54].

These limitations provide a strong rationale for developing biomarker-guided therapies, immunotherapy, CRISPR-Cas9 gene editing, nanotechnology-based delivery systems, therapeutic vaccines, and other precision approaches for cervical cancer.

4. Conventional Chemotherapy in Cervical Cancer

Conventional chemotherapy remains an important component of cervical cancer management, particularly in locally advanced, recurrent, and metastatic disease. Treatment selection depends on FIGO stage, tumor characteristics, previous therapy, performance status, and metastatic burden. Platinum agents, particularly cisplatin and carboplatin, constitute the principal backbone of systemic treatment.

4.1 Platinum Agents

Cisplatin is the major platinum agent used concurrently with radiotherapy in locally advanced cervical cancer. Following intracellular aquation, cisplatin forms predominantly intra- and interstrand DNA cross-links, producing DNA distortion, replication arrest, cell-cycle disruption, and apoptosis. It also functions as a radiosensitizer, enhancing the efficacy of radiotherapy [51–53]. In recurrent/metastatic disease, cisplatin has demonstrated response rates of approximately 15–25%, increasing to approximately 46% when combined with paclitaxel [53]. Major toxicities include nephrotoxicity, nausea, myelosuppression, ototoxicity, neuropathy, and electrolyte disturbances. Resistance may develop through enhanced DNA repair, increased drug efflux, glutathione-mediated detoxification, reduced intracellular accumulation, and impaired apoptotic signaling [52–54].

Carboplatin, a second-generation platinum analogue, produces DNA cross-links through a mechanism similar to cisplatin but generally causes less nephrotoxicity and gastrointestinal toxicity. However, myelosuppression, particularly thrombocytopenia, is more prominent. Carboplatin is commonly combined with paclitaxel and may be preferred in selected patients who cannot tolerate cisplatin [51–53].

4.2 Taxanes and Other Agents

Paclitaxel binds β-tubulin and stabilizes microtubules, preventing their normal depolymerization and producing mitotic arrest followed by apoptosis. It is frequently combined with cisplatin or carboplatin and remains an important component of systemic combination regimens. Major toxicities include peripheral neuropathy, neutropenia, alopecia, myalgia, and hypersensitivity reactions [51–53].

Other conventional agents include gemcitabine, topotecan, irinotecan, ifosfamide, and vinorelbine. Gemcitabine inhibits DNA synthesis through nucleotide depletion and DNA incorporation, whereas topotecan and irinotecan inhibit topoisomerase I and induce replication-associated DNA damage. Ifosfamide produces DNA cross-links following hepatic activation, while vinorelbine inhibits microtubule assembly. These agents have demonstrated varying activity in recurrent/metastatic cervical cancer but are limited by myelosuppression, diarrhea, nephrotoxicity, neurotoxicity, hemorrhagic cystitis, and other adverse effects [51–55].

4.3 Chemoresistance and Limitations

Chemotherapeutic efficacy is restricted by intrinsic and acquired resistance, involving increased drug efflux through ABC transporters, enhanced DNA repair, altered Bcl-2/Bax and caspase signaling, cell-cycle dysregulation, cancer stem-like cells, and protective tumor-microenvironmental factors such as hypoxia, abnormal vasculature, fibroblasts, and immunosuppressive cells [54], Additional limitations include poor tumor selectivity, systemic toxicity, tumor heterogeneity, platinum resistance, recurrence, metastatic progression, and impaired quality of life.

4.4 Future Perspective

Although chemotherapy remains a therapeutic backbone, its limitations support integration with radiotherapy, immune checkpoint inhibitors, anti-angiogenic agents, antibody–drug conjugates, targeted therapies, and nanotechnology-based delivery systems. Nanoparticles may enhance tumor-specific drug delivery and facilitate co-delivery of therapeutic agents, while CRISPR-Cas9-based strategies targeting HPV oncogenes such as E6/E7 represent a promising precision approach. Thus, conventional chemotherapy is increasingly viewed not as an isolated modality but as a foundation for multimodal and precision-based cervical cancer therapy [51–54].

5. Anti-Angiogenic Targeted Therapy

Angiogenesis, the formation of new blood vessels from pre-existing vasculature, is essential for tumor growth, invasion, and metastasis. In cervical cancer, persistent HPV infection, hypoxia, inflammation, and oncogenic signaling promote angiogenic activity, particularly through the VEGF/VEGFR pathway [63–64]. Hypoxia stabilizes HIF-1α, which increases VEGF-A expression and activates VEGFR-2, promoting endothelial-cell proliferation, migration, vascular permeability, and new-vessel formation.

Bevacizumab, a humanized monoclonal antibody targeting VEGF-A, is the most clinically established anti-angiogenic therapy in cervical cancer. By neutralizing circulating VEGF-A, it reduces VEGFR signaling and suppresses tumor-associated angiogenesis [63,65]. Its clinical benefit was demonstrated in the GOG-0240 phase III trial, which evaluated bevacizumab combined with chemotherapy in patients with recurrent, persistent, or metastatic cervical cancer [66]. Addition of bevacizumab increased median overall survival from approximately 13.3 to 17.0 months, improved progression-free survival (8.2 vs 5.9 months), and increased objective response rates (48% vs 36%) [66]. Final analysis confirmed a sustained survival benefit, with median overall survival of 16.8 vs 13.3 months [66].

Despite its efficacy, bevacizumab is associated with important toxicities, including hypertension, proteinuria, bleeding, thromboembolism, impaired wound healing, gastrointestinal perforation, and fistula formation [66,67]. Fistula risk is particularly relevant in previously irradiated patients.

Resistance may develop through alternative angiogenic pathways, increased hypoxia/HIF signaling, vessel co-option, pericyte protection, and tumor-microenvironment adaptation [64,65]. Future strategies therefore include combining anti-angiogenic therapy with immune checkpoint inhibitors, nanotechnology-based delivery, hypoxia-targeting approaches, and gene-editing strategies. Thus, VEGF inhibition remains an important component of targeted therapy for advanced cervical cancer.

6. Immunotherapy

Immunotherapy has transformed cervical cancer treatment by restoring or enhancing antitumor immune responses rather than directly targeting rapidly proliferating cells. This approach is particularly relevant to HPV-associated cervical cancer because persistent high-risk HPV infection produces viral antigens, especially E6 and E7, while contributing to an immunosuppressive tumor microenvironment [69,70].

The most clinically established strategy is immune checkpoint inhibition, particularly targeting the PD-1/PD-L1 pathway. PD-1 is an inhibitory receptor on activated T cells, while PD-L1 expressed by tumor and immune cells can suppress T-cell activation and facilitate immune escape. Pembrolizumab, a monoclonal antibody against PD-1, blocks PD-1 interaction with PD-L1/PD-L2, thereby restoring T-cell activity and enhancing tumor-cell destruction [69–71].

PD-L1 expression is commonly assessed using the Combined Positive Score (CPS), which incorporates PD-L1-positive tumor cells and immune cells. A CPS ≥1 is an important biomarker threshold for pembrolizumab treatment in relevant cervical cancer settings [71].

The KEYNOTE-826 phase III trial established pembrolizumab plus platinum-based chemotherapy, with or without bevacizumab, as an important systemic treatment strategy for persistent, recurrent, or metastatic cervical cancer. In PD-L1 CPS ≥1 patients, pembrolizumab improved progression-free survival (10.4 vs 8.2 months; HR 0.62) and overall survival, with 24-month survival of approximately 53.0% vs 41.7% [72]. Combining pembrolizumab with chemotherapy and bevacizumab provides complementary cytotoxic, immune-restoring, and anti-angiogenic effects.

The KEYNOTE-A18 trial further extended immunotherapy into newly diagnosed high-risk locally advanced disease. Pembrolizumab combined with chemoradiotherapy followed by maintenance pembrolizumab improved progression-free survival, with 24-month rates of approximately 68% vs 57% (HR 0.70), and subsequent analysis demonstrated an overall survival benefit [72,73].

Despite these advances, resistance and immune-related toxicities remain important limitations. Alternative checkpoints such as CTLA-4, TIGIT, LAG-3, and TIM-3, together with TIL therapy, HPV-specific T cells, therapeutic HPV vaccines, and CAR-T approaches, are being investigated [71,74,75].

Future cervical cancer immunotherapy may integrate HPV E6/E7 targeting, checkpoint blockade, angiogenesis inhibition, tumor-microenvironment modulation, and CRISPR-based immune-cell engineering, potentially enabling more durable and personalized antitumor responses.

7. Antibody–Drug Conjugates

Antibody–drug conjugates (ADCs) are modern targeted therapies that combine the tumor-selective recognition of monoclonal antibodies with the potent cytotoxic activity of small-molecule payloads [78–80]. An ADC consists of three major components: a monoclonal antibody, chemical linker, and cytotoxic payload. The antibody binds a tumor-associated antigen, followed by internalization and intracellular release of the payload, resulting in selective tumor-cell killing.

Tisotumab vedotin (TV) is an important ADC in cervical cancer that targets tissue factor (TF/CD142), a transmembrane protein frequently expressed in cervical cancer. TV consists of an anti-TF monoclonal antibody, a protease-cleavable linker, and monomethyl auristatin E (MMAE), a potent microtubule-disrupting agent [81–83]. Its mechanism involves TF binding → ADC internalization → intracellular linker processing → MMAE release → tubulin disruption → mitotic arrest → apoptosis.

TF has functions beyond coagulation and may contribute to tumor survival, angiogenesis, migration, invasion, and metastasis, making it an attractive therapeutic target [81,83]. In addition to MMAE-mediated cytotoxicity, the antibody component may contribute to immune-mediated mechanisms such as antibody-dependent cellular cytotoxicity and phagocytosis.

Clinical development of TV focused on recurrent or metastatic cervical cancer after progression following chemotherapy. In the phase II innovaTV 204 study, TV produced an objective response rate of approximately 24%, with a median duration of response of about 8.3 months.[88] The subsequent phase III innovaTV 301 trial demonstrated improved overall survival (11.5 vs 9.5 months; HR ≈0.70) and progression-free survival (4.2 vs 2.9 months; HR ≈0.67) compared with investigator-choice chemotherapy [86,87].

Important toxicities include ocular adverse events, peripheral neuropathy, and bleeding, requiring appropriate monitoring and supportive measures [84,88]. Resistance may arise through reduced or heterogeneous TF expression, impaired internalization, altered intracellular trafficking, payload resistance, and increased drug efflux.

Future ADC development may focus on novel targets, improved linkers and payloads, biomarker-guided selection, bispecific or dual-payload ADCs, and combinations with immunotherapy or anti-angiogenic therapy. Thus, tisotumab vedotin represents an important advance toward biomarker-directed treatment of advanced cervical cancer.

8. Treatment Resistance in Cervical Cancer

Treatment resistance remains a major barrier to successful cervical cancer management. Despite advances in surgery, radiotherapy, chemotherapy, anti-angiogenic therapy, immune checkpoint inhibitors, and antibody–drug conjugates (ADCs), many patients develop intrinsic or acquired resistance, resulting in persistence, recurrence, progression, or metastasis [98–100]. Resistance is multifactorial and involves alterations in DNA repair, drug transport and metabolism, apoptosis, cellular signaling, immune recognition, tumor heterogeneity, cancer stemness, and the tumor microenvironment (TME) [98,101,102]. These mechanisms frequently overlap across treatment modalities.

8.1 Chemoresistance

Resistance to platinum compounds, taxanes, and other cytotoxic agents may arise through several mechanisms. Enhanced DNA repair, involving nucleotide excision repair, homologous recombination, and non-homologous end joining, facilitates resolution of chemotherapy- and radiotherapy-induced DNA damage [98,101]. Increased activity of ATP-binding cassette (ABC) transporters, including ABCB1/P-glycoprotein, ABCC1, and ABCG2, promotes drug efflux and reduces intracellular drug concentrations [99,104]. Altered drug metabolism and detoxification can further decrease effective drug exposure.

Defective apoptosis is another important mechanism. Increased expression of anti-apoptotic proteins such as BCL-2, BCL-XL, and MCL-1, together with impaired pro-apoptotic signaling, allows damaged cells to survive [100,105]. In HPV-associated cervical cancer, viral E6-mediated degradation of p53 compromises DNA-damage checkpoints and apoptosis, thereby contributing to treatment resistance [101,106].

Cancer stem cells (CSCs) also contribute to resistance through enhanced DNA repair, antioxidant defenses, drug-efflux activity, quiescence, and self-renewal, allowing them to survive treatment and regenerate tumors [102,107]. Furthermore, increased antioxidant systems, including glutathione, superoxide dismutase, and catalase, can neutralize therapy-induced reactive oxygen species. Epithelial–mesenchymal transition (EMT), characterized by reduced E-cadherin and increased vimentin/N-cadherin, promotes stemness, invasion, metastasis, and therapeutic tolerance [102,108].

8.2 Immunotherapy Resistance

Resistance to immune checkpoint inhibitors may be primary or acquired [109,110]. Defective antigen processing and presentation involving MHC class I, β2-microglobulin, or antigen-processing machinery can reduce tumor recognition by T cells. Persistent antigen exposure may induce T-cell exhaustion, characterized by reduced cytotoxicity and increased inhibitory receptors such as PD-1, CTLA-4, TIGIT, LAG-3, and TIM-3 [119,110]. In addition, Tregs, tumor-associated macrophages (TAMs), and myeloid-derived suppressor cells (MDSCs) create an immunosuppressive TME that limits effective CD8+ T-cell responses [111]. Loss of tumor or HPV-associated antigens, including E6/E7, may further facilitate immune escape.

8.3 Targeted-Therapy and Adaptive Resistance

Targeted therapies can be compromised by alternative pathway activation, target alteration, feedback signaling, tumor heterogeneity, and adaptive cellular responses [113]. Compensatory activation of PI3K/AKT/mTOR, MAPK/ERK, JAK/STAT, NF-κB, Wnt/β-catenin, or TGF-β pathways may restore survival signaling. For ADCs, reduced or heterogeneous target expression can decrease antibody binding, internalization, and payload delivery. Hypoxia, cancer-associated fibroblasts, TAMs, extracellular matrix remodeling, and other TME components can additionally protect tumor cells and restrict drug penetration.

8.4 Strategies to Overcome Resistance and Role of CRISPR-Cas9

Because resistance mechanisms are interconnected, mechanism-driven combination therapy represents an important therapeutic strategy. Potential approaches include combining chemotherapy with DNA-repair or apoptosis-modulating agents, checkpoint inhibitors with alternative immune-checkpoint blockade, anti-angiogenic therapy with immunotherapy, and ADCs with immune-based treatments. CSC-, TAM-, MDSC-, and hypoxia-directed strategies may further improve therapeutic efficacy.

CRISPR-Cas9 provides an emerging precision approach for overcoming resistance by directly modifying genes involved in drug efflux, DNA repair, apoptosis, stemness, immune evasion, and survival signaling. In HPV-positive cervical cancer, targeting the viral E6/E7 oncogenes may restore p53/Rb-associated tumor-suppressive functions and enhance cellular susceptibility to conventional and immune-based therapies. Thus, understanding resistance mechanisms provides a critical bridge between current multimodal treatment and future precision gene-editing strategies for durable cervical cancer control [98–117].

9. Conclusion

Cervical cancer remains a major global health challenge despite substantial advances in screening, HPV vaccination, surgery, radiotherapy, chemotherapy, targeted therapy, immunotherapy, and antibody–drug conjugates (ADCs). The burden remains disproportionately high in low- and middle-income countries because of inequalities in vaccination, screening, early diagnosis, treatment access, and healthcare infrastructure. Persistent infection with high-risk human papillomavirus (HPV), particularly HPV-16 and HPV-18, is the principal etiological factor. The viral oncogenes E6 and E7 contribute critically to malignant transformation through disruption of the p53 and retinoblastoma (Rb) tumor-suppressor pathways. The molecular pathogenesis of cervical cancer involves complex interactions among PI3K/AKT/mTOR, MAPK/ERK, JAK/STAT, NF-κB, Wnt/β-catenin, TGF-β, VEGF, and PD-1/PD-L1 pathways [26–38]. Dysregulation of these pathways promotes uncontrolled proliferation, genomic instability, apoptosis resistance, angiogenesis, epithelial–mesenchymal transition, invasion, metastasis, and immune evasion. Molecular markers including HPV E6/E7, p53, Rb, p16INK4a, Ki-67, VEGF, EGFR, PD-L1, MDM2, and NFAT1 may therefore contribute to understanding tumor behavior and therapeutic response. Current treatment is largely determined by disease stage. Surgery remains important for appropriately selected early-stage patients, whereas external-beam radiotherapy, brachytherapy, and concurrent cisplatin-based chemoradiation remain fundamental approaches for locally advanced disease. In recurrent or metastatic disease, systemic chemotherapy involving platinum agents, taxanes, gemcitabine, topotecan, irinotecan, and other cytotoxic drugs continues to play an important role. However, toxicity and treatment resistance remain major limitations. The development of bevacizumab has expanded targeted treatment by inhibiting VEGF-mediated angiogenesis and improving outcomes when combined with chemotherapy in advanced disease [63–68]. Similarly, immune checkpoint inhibition has transformed the therapeutic landscape. Pembrolizumab, particularly in combination with chemotherapy with or without bevacizumab, has demonstrated clinically meaningful benefits in advanced cervical cancer, while KEYNOTE-A18 has further supported the incorporation of pembrolizumab with chemoradiotherapy in selected newly diagnosed locally advanced disease. The emergence of tisotumab vedotin, an ADC targeting tissue factor and delivering the cytotoxic payload MMAE, represents another important advance [78–97]. Its demonstrated survival benefit in previously treated recurrent/metastatic cervical cancer highlights the potential of targeted intracellular drug delivery. Nevertheless, ocular toxicity, peripheral neuropathy, bleeding, target heterogeneity, and acquired resistance remain important challenges. Treatment resistance is a common limitation across therapeutic modalities. Chemoresistance may involve enhanced DNA repair, ABC transporter-mediated drug efflux, apoptosis inhibition, oxidative-stress adaptation, EMT, and cancer stem cells, whereas immunotherapy resistance may involve impaired antigen presentation, T-cell exhaustion, alternative immune checkpoints, and an immunosuppressive tumor microenvironment. Collectively, these findings demonstrate that cervical cancer is a biologically heterogeneous and continuously evolving disease requiring multimodal and personalized therapeutic strategies. The HPV E6/E7 axis provides an especially attractive opportunity for precision intervention. CRISPR-Cas9 may potentially target E6/E7 and other genes associated with proliferation, immune evasion, metastasis, and treatment resistance. Future research should therefore focus on biomarker-guided therapy, rational therapeutic combinations, novel immunotherapies, ADCs, HPV-directed approaches, and gene-editing technologies. Integration of these emerging strategies with established treatments may ultimately provide more precise, durable, and individualized management of cervical cancer and contribute to reducing its global morbidity and mortality.

References

“I would like to express my sincere gratitude to Ms. Sarah Jacobs, Editorial Coordinator of the IJCCR, for her excellent collaboration and exceptional support throughout the entire process, from article submission and peer review to financial matters and successful publication. Everything went very quickly and smoothly. I would also like to thank the reviewers, whose comments were helpful and contributed to an even better article. I wholeheartedly recommend this deservedly renowned journal to my colleagues for publication.” Best regards, Andreas Schapowal.

img

Dr Andreas Schapowal

Dear Editorial Team, Clinical Medical Reviews and Reports. My experience with the journal was highly positive. The peer-review process was rigorous, constructive, and completed in a timely manner. The reviewers provided valuable comments that helped improve the quality and clarity of our manuscript. The editorial office was professional, responsive, and supportive throughout all stages of the publication process. Communication was clear and efficient, and any questions were addressed promptly. Overall, I found the journal to maintain high scientific standards and an excellent publication workflow. I would be pleased to consider submitting future work to this journal. Best wishes from, Elena Popa.

img

Dr Elena Popa

It was my pleasure to submit my testimonial concerning the Reviewer Board of our Scientific Journal “Brain and Neurological Disorders”. The Reviewers focused on some modifications and their contribution was helpful. The ladies of our Editorial Office were also supported my efforts. It was my honor to have such a co-operation and I am looking forward for more collaboration.

img

Dr Nikolaos Andreas Chrysanthakopoulos

Dear Grace Pierce, Editorial Coordinator of Journal of Clinical Research and Reports, Thank you for the speedy and efficient peer review process. I appreciate the fact that your peer reviewers do not take months to respond like with some other journals. I would also like to thank the editorial office for responding quickly to my questions. It is an excellent journal. I plan to submit more manuscripts in the future. Best wishes from, Robert W. McGee

img

Robert W McGee

Dear Grace Pierce, Editorial Coordinator of Journal of Clinical Research and Reports, Working with you and your team on our recent publication in JCRR has been a truly wonderful and enjoyable experience. The responses were prompt, and the reviewers were patient, constructive, and highly professional. One reviewer in particular gave me the feeling that a professor was carefully reading and commenting on my coursework, which was deeply touching. The entire process was straightforward and hassle‑free, with no tedious online forms to complete. I highly recommend this journal. Best wishes from, DR Aibing Rao, Head of R&D

img

Aibing Rao

I Appreciate the Opportunity to Share my Experience with the Journal of Clinical Research and Reports. The peer review process was timely and constructive, and the feedback provided helped improve the quality of our manuscript. The editorial office was professional, responsive, and supportive throughout the process, ensuring smooth communication and efficient handling of the submission. Overall, it was a positive experience collaborating with your team.

img

Kashani Mehdi

Dear Mercy Grace, Editorial Coordinator of Obstetrics Gynecology and Reproductive Sciences, We would like to express our gratitude for your help at all stages of publishing and editing the article. The editors of the magazine answer all the necessary questions and help at every stage. We will definitely continue to cooperate and publish other works in the Obstetrics Gynecology and Reproductive Sciences! Best wishes from, Alla Konstantinovna Politova,

img

Alla Konstantinovna Politova

Dear Maria Emerson, Editorial Coordinator of International Journal of Clinical Case Reports and Reviews, What distinguishes International Journal of Clinical Case Report and Review is not only the scientific rigor of its publications, but the intellectual climate in which research is evaluated. The submission process is refreshingly free of unnecessary formal barriers and bureaucratic rituals that often complicate academic publishing without adding real value. The peer-review system is demanding yet constructive, guided by genuine scientific dialogue rather than hierarchical or authoritarian attitudes. Reviewers act as collaborators in improving the manuscript, not as gatekeepers imposing arbitrary standards. This journal offers a rare balance: high methodological standards combined with a respectful, transparent, and supportive editorial approach. In an era where publishing can feel more burdensome than research itself, this platform restores the original purpose of peer review — to refine ideas, not to obstruct them Prof. Perlat Kapisyzi, FCCP PULMONOLOGIST AND THORACIC IMAGING.

img

Perlat Kapisyzi

Dear Reader: We have published several articles in the Auctores Publishing, LLC, journal, Clinical Medical Reviews and Reports in recent years (CMRR). This is an ‘open access’ journal and the following are our observations. From the initial invitation to submit an article, to the final edits of galley proofs, we have found CMRR personnel to be professional, responsive, rapid and thorough. This entire process begins with Catherine Mitchell, Editorial Coordinator. She is simply outstanding, and, I believe, unparalleled in her capacity. I cannot imagine a more responsive and dedicated Editorial Coordinator. As I read the dates and timing of her correspondence with us, it seems that she never sleeps. I hope Auctores Publishing, LLC, appreciates her efforts as much as these authors do. Thank you to Auctores Publishing, LLC, to the Editorial Staff/Board, and to Catherine Mitchell from a grateful author(s).

img

Dr Gary Merrill

Dear Maria Emerson, Editorial Coordinator of - Journal of Clinical Research and Reports. ''I am pleased to provide this testimonial following the publication of our recent case report in this journal. The peer review process was rigorous, constructive, thorough, and conducted in a timely manner. The reviewers’ comments were thoughtful, detailed, and highly constructive, contributing substantially to the refinement, clarity, and scientific robustness of our manuscript. The process was conducted with professionalism and academic integrity throughout. The support provided by the editorial office was exemplary. Communication was consistently prompt, clear, and courteous at all stages of the submission and publication process. The editorial team demonstrated a high level of organization and responsiveness, ensuring that all queries were addressed efficiently and that the process remained transparent and well-coordinated. The overall quality of the journal is reflected in its strong editorial standards, commitment to scientific excellence, and dedication to publishing clinically meaningful research. It has been a privilege to publish our work in this journal, and we would welcome the opportunity to contribute further in the future.'' Best wishes from, Dr. Efstratios Trogkanis, Cardiologist.

img

Dr Efstratios Troganis

Dear Grace Pierce, Editorial Coordinator of the journal IJCCR, I had a very positive experience with Auctores - Journal throughout the publication process. The Editorial Team was highly responsive, professional, and supportive at every stage. I would like to extend my sincere thanks to the Editor: Grace Pierce, for her guidance and assistance. The peer-review process was smooth and constructive, helping improve the quality of my work. I would gladly recommend Auctores Journal to fellow researchers and authors. Dr. SABITA SINHA, Medical Oncologist, MD (Electro Homeopathy).

img

Dr SABITA SINHA

Dear Mayra Duenas, Editorial Coordinator of the journal IJCCR, I write here a little on my experience as an author submitting to the International Journal of Clinical Case Reports and Reviews (IJCCR). This was my first submission to IJCCR and my manuscript was inherently an outsider’s effort. It attempted to broadly identify and then make some sense of life’s under-appreciated mysteries. I initially had responded to a request for possible submissions. I then contacted IJCCR with a tentative topic for a manuscript. They quickly got back with an approval for the submission, but with a particular requirement that it be medically relevant. I then put together a manuscript and submitted it. After the usual back-and-forth over forms and formality, the manuscript was sent off for reviews. Within 2 weeks I got back 4 reviews which were both helpful and also surprising. Surprising in that the topic was somewhat foreign to medical literature. My subsequent updates in response to the reviewer comments went smoothly and in short order I had a series of proofs to evaluate. All in all, the whole publication process seemed outstanding. It was both helpful in terms of the paper’s content and also in terms of its efficient and friendly communications. Thank you all very much. Sincerely, Ted Christopher, Rochester, NY.

img

Dr Ted Christopher

International Journal of Clinical Case Reports and Reviews is a high quality journal that has a clear and concise submission process. The peer review process was comprehensive and constructive. Support from the editorial office was excellent, since the administrative staff were responsive. The journal provides a fast and timely publication timeline.

img

Joel Yat Seng Wong

Dear Cecilia Lilly, Editorial Coordinator, Endocrinology and Disorders, Thank you so much for your quick response regarding reviewing and all process till publishing our manuscript entitled: Prevalence of Pre-Diabetes and its Associated Risk Factors Among Nile College Students, Sudan. Best regards, Dr Mamoun Magzoub.

img

Dr Mamoun Magzoub

Dear Editorial Team, Clinical Cardiology and Cardiovascular Interventions. I am really grateful for the peers review; their feedback gave me the opportunity to reflect on the message and impact of my work and to ameliorate the article. The editors did a great job in addition by encouraging me to continue with the process of publishing.

img

Baciulescu Laura

Dear Mayra Duenas, Editorial Coordinator of ‘International Journal of Clinical Case Reports and Reviews Herewith I confirm an optimal peer review process and a great support of the editorial office of the present journal

img

Christoph Maurer

Dear Maria Emerson, Editorial Coordinator of ‘International Journal of Clinical Case Reports and Reviews’, I appreciate the opportunity to publish my article with your journal. The editorial office provided clear communication during the submission and review process, and I found the overall experience professional and constructive. Best regards, Elena Salvatore.

img

Dr Elena Salvatore

Dear Editorial Team, Journal-Clinical Cardiology and Cardiovascular Interventions, “Publishing my article with Clinical Cardiology and Cardiovascular Interventions has been a highly positive experience. The peer-review process was rigorous yet supportive, offering valuable feedback that strengthened my work. The editorial team demonstrated exceptional professionalism, prompt communication, and a genuine commitment to maintaining the highest scientific standards. I am very pleased with the publication quality and proud to be associated with such a reputable journal.” Warm regards, Dr. Mahmoud Kamal Moustafa Ahmed

img

Mahmoud Kamal Moustafa Ahmed

Dear Editorial Team, Clinical Cardiology and Cardiovascular Interventions. It was truly a rewarding experience to work with the journal “Clinical Cardiology and Cardiovascular Interventions”. The peer review process was insightful and encouraging, helping us refine our work to a higher standard. The editorial office offered exceptional support with prompt and thoughtful communication. I highly value the journal’s role in promoting scientific advancement and am honored to be part of it. Best regards, Meng-Jou Lee, MD, Department of Anesthesiology, National Taiwan University Hospital.

img

Dr Meng-JouLe

Dear Maria Emerson, Editorial Coordinator, Journal of Clinical Research and Reports. Thank you for publishing our case report: "Clinical Case of Effective Fetal Stem Cells Treatment in a Patient with Autism Spectrum Disorder" within the "Journal of Clinical Research and Reports" being submitted by the team of EmCell doctors from Kyiv, Ukraine. We much appreciate a professional and transparent peer-review process from Auctores. All research Doctors are so grateful to your Editorial Office and Auctores Publishing support! I amiably wish our article publication maintained a top quality of your International Scientific Journal. My best wishes for a prosperity of the Journal of Clinical Research and Reports. Hope our scientific relationship and cooperation will remain long lasting. Thank you very much indeed. Kind regards, Dr. Andriy Sinelnyk Cell Therapy Center EmCell

img

Dr Andriy Sinelnyk

I recommend without hesitation submitting relevant papers on medical decision making to the International Journal of Clinical Case Reports and Reviews. I am very grateful to the editorial staff. Maria Emerson was a pleasure to communicate with. The time from submission to publication was an extremely short 3 weeks. The editorial staff submitted the paper to three reviewers. Two of the reviewers commented positively on the value of publishing the paper. The editorial staff quickly recognized the third reviewer’s comments as an unjust attempt to reject the paper. I revised the paper as recommended by the first two reviewers.

img

Edouard Kujawski

Dear Chrystine Mejia, Editorial Coordinator, Journal of Neurodegeneration and Neurorehabilitation. “The peer review process was efficient and constructive, and the editorial office provided excellent communication and support throughout. The journal ensures scientific rigor and high editorial standards, while also offering a smooth and timely publication process. We sincerely appreciate the work of the editorial team in facilitating the dissemination of innovative approaches such as the Bonori Method.” Best regards, Dr. Matteo Bonori.

img

Dr Matteo Bonori

Dear Maria Emerson, Editorial Coordinator, we have deeply appreciated the professionalism demonstrated by the International Journal of Clinical Case Reports and Reviews. The reviewers have extensive knowledge of our field and have been very efficient and fast in supporting the process. I am really looking forward to further collaboration. Thanks. Best regards, Dr. Claudio Ligresti

img

Dr Claudio Ligresti

Dear Ms. Mayra Duenas, Editorial Coordinator, International Journal of Clinical Case Reports and Reviews. “The International Journal of Clinical Case Reports and Reviews represented the “ideal house” to share with the research community a first experience with the use of the Simeox device for speech rehabilitation. High scientific reputation and attractive website communication were first determinants for the selection of this Journal, and the following submission process exceeded expectations: fast but highly professional peer review, great support by the editorial office, elegant graphic layout. Exactly what a dynamic research team - also composed by allied professionals - needs!" From, Chiara Beccaluva, PT - Italy.

img

Dr Chiara Giuseppina Beccaluva

Dear Clarissa Eric, Editorial Coordinator, Journal of Clinical Case Reports and Studies, Auctores Publishing LLC, USA Office: +1-(302)-520-2644. I would like to express my sincere appreciation for the efficient and professional handling of my case report by the ‘Journal of Clinical Case Reports and Studies’. The peer review process was not only fast but also highly constructive—the reviewers’ comments were clear, relevant, and greatly helped me improve the quality and clarity of my manuscript. I also received excellent support from the editorial office throughout the process. Communication was smooth and timely, and I felt well guided at every stage, from submission to publication. The overall quality and rigor of the journal are truly commendable. I am pleased to have published my work with Journal of Clinical Case Reports and Studies, and I look forward to future opportunities for collaboration. Sincerely, Aline Tollet, UCLouvain.

img

Dr Aline Tollet

Dear Chrystine Mejia, Editorial Coordinator, Journal of Neurodegeneration and Neurorehabilitation, Auctores Publishing LLC, We would like to thank the editorial team for the smooth and high-quality communication leading up to the publication of our article in the Journal of Neurodegeneration and Neurorehabilitation. The reviewers have extensive knowledge in the field, and their relevant questions helped to add value to our publication. Kind regards, Dr. Ravi Shrivastava.

img

Dr Ravi Shrivastava

Dear Clarissa Eric, Editorial Coordinator, Journal of Clinical Case Reports and Studies, I would like to express my deep admiration for the exceptional professionalism demonstrated by your journal. I am thoroughly impressed by the speed of the editorial process, the substantive and insightful reviews, and the meticulous preparation of the manuscript for publication. Additionally, I greatly appreciate the courteous and immediate responses from your editorial office to all my inquiries. Best Regards, Dariusz Ziora

img

Dariusz Ziora

Dear Ashley Rosa, Editorial Coordinator, International Journal of Clinical Case Reports and Reviews, Auctores Publishing LLC. Thank you for publishing our article, Exploring Clozapine's Efficacy in Managing Aggression: A Multiple Single-Case Study in Forensic Psychiatry in the international journal of clinical case reports and reviews. We found the peer review process very professional and efficient. The comments were constructive, and the whole process was efficient. On behalf of the co-authors, I would like to thank you for publishing this article. With regards, Dr. Jelle R. Lettinga.

img

Dr Jelle Lettinga

Dear Jessica Magne, Editorial Coordinator, Clinical Cardiology and Cardiovascular Interventions, Auctores Publishing LLC. The peer review process of the journal of Clinical Cardiology and Cardiovascular Interventions was excellent and fast, as was the support of the editorial office and the quality of the journal. Kind regards Walter F. Riesen Prof. Dr. Dr. h.c. Walter F. Riesen.

img

Dr Walter F Riesen

Dear Erin Aust, Editorial Coordinator, Journal of General Medicine and Clinical Practice. We are pleased to share our experience with the “Journal of General Medicine and Clinical Practice”, following the successful publication of our article. The peer review process was thorough and constructive, helping to improve the clarity and quality of the manuscript. We are especially thankful to Ms. Erin Aust, the Editorial Coordinator, for her prompt communication and continuous support throughout the process. Her professionalism ensured a smooth and efficient publication experience. The journal upholds high editorial standards, and we highly recommend it to fellow researchers seeking a credible platform for their work. Best wishes By, Dr. Rakhi Mishra.

img

Dr Rakhi Mishra

Dr Hala Al Shaikh This is to acknowledge that the peer review process for the article ’ A Novel Gnrh1 Gene Mutation in Four Omani Male Siblings, Presentation and Management ’ sent to the International Journal of Clinical Case Reports and Reviews was quick and smooth. The editorial office was prompt with easy communication.

img

Hala Al Shaikh

Dear Agrippa Hilda, Editorial Coordinator, Journal of Neuroscience and Neurological Surgery. The entire process including article submission, review, revision, and publication was extremely easy. The journal editor was prompt and helpful, and the reviewers contributed to the quality of the paper. Thank you so much! Eric Nussbaum, MD

img

Dr Eric S Nussbaum

Dear Ashley Rosa, Editorial Coordinator, International Journal of Clinical Case Reports and Reviews. Many thanks for publishing this manuscript after I lost confidence the editors were most helpful, more than other journals Best wishes from, Susan Anne Smith, PhD. Australian Breastfeeding Association.

img

Dr Susan Anne Smith

Dear Maria Emerson, Editorial Coordinator, International Journal of Clinical Case Reports and Reviews, Auctores Publishing LLC. I am delighted to have published our manuscript, "Acute Colonic Pseudo-Obstruction (ACPO): A rare but serious complication following caesarean section." I want to thank the editorial team, especially Maria Emerson, for their prompt review of the manuscript, quick responses to queries, and overall support. Yours sincerely Dr. Victor Olagundoye.

img

Dr Victor Olagundoye

Dear Jessica Magne, Editorial Coordinator, Clinical Cardiology and Cardiovascular Interventions, Auctores Publishing LLC. I appreciate the journal (JCCI) editorial office support, the entire team leads were always ready to help, not only on technical front but also on thorough process. Also, I should thank dear reviewers’ attention to detail and creative approach to teach me and bring new insights by their comments. Surely, more discussions and introduction of other hemodynamic devices would provide better prevention and management of shock states. Your efforts and dedication in presenting educational materials in this journal are commendable. Best wishes from, Farahnaz Fallahian.

img

Dr Farahnaz Fallahian

Dear Ashley Rosa, Editorial Coordinator of the journal - Psychology and Mental Health Care. " The process of obtaining publication of my article in the Psychology and Mental Health Journal was positive in all areas. The peer review process resulted in a number of valuable comments, the editorial process was collaborative and timely, and the quality of this journal has been quickly noticed, resulting in alternative journals contacting me to publish with them." Warm regards, Susan Anne Smith, PhD. Australian Breastfeeding Association.

img

Dr Susan Anne Smith

Dear Jessica, and the super professional team of the ‘Clinical Cardiology and Cardiovascular Interventions’ I am sincerely grateful to the coordinated work of the journal team for the no problem with the submission of my manuscript: “Cardiometabolic Disorders in A Pregnant Woman with Severe Preeclampsia on the Background of Morbid Obesity (Case Report).” The review process by 5 experts was fast, and the comments were professional, which made it more specific and academic, and the process of publication and presentation of the article was excellent. I recommend that my colleagues publish articles in this journal, and I am interested in further scientific cooperation. Sincerely and best wishes, Dr. Oleg Golyanovskiy.

img

Dr Oleg Golyanovski

To Dear Erin Aust – Editorial Coordinator of Journal of General Medicine and Clinical Practice! I declare that I am absolutely satisfied with your work carried out with great competence in following the manuscript during the various stages from its receipt, during the revision process to the final acceptance for publication. Thank Prof. Elvira Farina

img

Dr Elvira Farina

My article, titled 'No Way Out of the Smartphone Epidemic Without Considering the Insights of Brain Research,' has been republished in the International Journal of Clinical Case Reports and Reviews. The review process was seamless and professional, with the editors being both friendly and supportive. I am deeply grateful for their efforts.

img

Gertraud Teuchert-Noodt

We found the peer review process quick and positive in its input. The support from the editorial officer has been very agile, always with the intention of improving the article and taking into account our subsequent corrections.

img

Dr David Vinyes

Dear Jessica Magne, with gratitude for the joint work. Fast process of receiving and processing the submitted scientific materials in “Clinical Cardiology and Cardiovascular Interventions”. High level of competence of the editors with clear and correct recommendations and ideas for enriching the article.

img

Dr Anyuta Ivanova

I thank the ‘Journal of Clinical Research and Reports’ for accepting this article for publication. This is a rigorously peer reviewed journal which is on all major global scientific data bases. I note the review process was prompt, thorough and professionally critical. It gave us an insight into a number of important scientific/statistical issues. The review prompted us to review the relevant literature again and look at the limitations of the study. The peer reviewers were open, clear in the instructions and the editorial team was very prompt in their communication. This journal certainly publishes quality research articles. I would recommend the journal for any future publications.

img

Dr Farooq Wandroo

"I am grateful for the opportunity of contributing to [International Journal of Clinical Case Reports and Reviews] and for the rigorous review process that enhances the quality of research published in your esteemed journal. I sincerely appreciate the time and effort of your team who have dedicatedly helped me in improvising changes and modifying my manuscript. The insightful comments and constructive feedback provided have been invaluable in refining and strengthening my work".

img

Dr Shweta Tiwari

To Dear Erin Aust, I would like to express my heartfelt appreciation for the opportunity to have my work published in this esteemed journal. The entire publication process was smooth and well-organized, and I am extremely satisfied with the final result. The Editorial Team demonstrated the utmost professionalism, providing prompt and insightful feedback throughout the review process. Their clear communication and constructive suggestions were invaluable in enhancing my manuscript, and their meticulous attention to detail and dedication to quality are truly commendable. Additionally, the support from the Editorial Office was exceptional. From the initial submission to the final publication, I was guided through every step of the process with great care and professionalism. The team's responsiveness and assistance made the entire experience both easy and stress-free. I am also deeply impressed by the quality and reputation of the journal. It is an honor to have my research featured in such a respected publication, and I am confident that it will make a meaningful contribution to the field.

img

Dr Tewodros Kassahun Tarekegn

I would like to express my sincere gratitude for the support and efficiency provided by the editorial office throughout the publication process of my article, “Delayed Vulvar Metastases from Rectal Carcinoma: A Case Report.” I greatly appreciate the assistance and guidance I received from your team, which made the entire process smooth and efficient. The peer review process was thorough and constructive, contributing to the overall quality of the final article. I am very grateful for the high level of professionalism and commitment shown by the editorial staff, and I look forward to maintaining a long-term collaboration with the International Journal of Clinical Case Reports and Reviews.

img

Cristina Berriozabal

Dear Agrippa Hilda- Editorial Coordinator of Journal of Neuroscience and Neurological Surgery, "The peer review process was very quick and of high quality, which can also be seen in the articles in the journal. The collaboration with the editorial office was very good."

img

Thomas Urban

I would like to offer my testimony in the support. I have received through the peer review process and support the editorial office where they are to support young authors like me, encourage them to publish their work in your esteemed journals, and globalize and share knowledge globally. I really appreciate your journal, peer review, and editorial office.

img

Zhao Jia

My experience publishing in International Journal of Clinical Case Reports and Reviews was exceptional. I Come forth to Provide a Testimonial Covering the Peer Review Process and the editorial office for the Professional and Impartial Evaluation of the Manuscript.

img

Luiz Sellmann

My experience publishing in Psychology and Mental Health Care was exceptional. The peer review process was rigorous and constructive, with reviewers providing valuable insights that helped enhance the quality of our work. The editorial team was highly supportive and responsive, making the submission process smooth and efficient. The journal's commitment to high standards and academic rigor makes it a respected platform for quality research. I am grateful for the opportunity to publish in such a reputable journal.

img

Sonila Qirko

My Testimonial Covering as fellowing: Lin-Show Chin. The peer reviewers process is quick and effective, the supports from editorial office is excellent, the quality of journal is high. I would like to collabroate with Internatioanl journal of Clinical Case Reports and Reviews.

img

Lin-Show Chin

Dealing with The Journal of Neurology and Neurological Surgery was very smooth and comprehensive. The office staff took time to address my needs and the response from editors and the office was prompt and fair. I certainly hope to publish with this journal again.Their professionalism is apparent and more than satisfactory. Susan Weiner

img

Dr Susan Weiner

Dear Editorial Coordinator of the Journal of Nutrition and Food Processing! "I would like to thank the Journal of Nutrition and Food Processing for including and publishing my article. The peer review process was very quick, movement and precise. The Editorial Board has done an extremely conscientious job with much help, valuable comments and advices. I find the journal very valuable from a professional point of view, thank you very much for allowing me to be part of it and I would like to participate in the future!”

img

Zsuzsanna Bene

Dear Monica Gissare, - Editorial Coordinator of Nutrition and Food Processing. ¨My testimony with you is truly professional, with a positive response regarding the follow-up of the article and its review, you took into account my qualities and the importance of the topic¨.

img

Dr Maria Regina Penchyna Nieto

Dear Dr. Jessica Magne, Editorial Coordinator 0f Clinical Cardiology and Cardiovascular Interventions, I hope this message finds you well. I want to express my utmost gratitude for your excellent work and for the dedication and speed in the publication process of my article titled "Navigating Innovation: Qualitative Insights on Using Technology for Health Education in Acute Coronary Syndrome Patients." I am very satisfied with the peer review process, the support from the editorial office, and the quality of the journal. I hope we can maintain our scientific relationship in the long term.

img

Dr Maria Dolores Gomez Barriga

Clinical Cardiology and Cardiovascular Interventions, I would like to express my sincerest gratitude for the trust placed in our team for the publication in your journal. It has been a true pleasure to collaborate with you on this project. I am pleased to inform you that both the peer review process and the attention from the editorial coordination have been excellent. Your team has worked with dedication and professionalism to ensure that your publication meets the highest standards of quality. We are confident that this collaboration will result in mutual success, and we are eager to see the fruits of this shared effort.

img

Maria Dolores Gomez Barriga

The peer reviewers process is quick and effective, the supports from editorial office is excellent, the quality of journal is high. I would like to collabroate with Internatioanl journal of Clinical Case Reports and Reviews journal clinically in the future time.

img

Lin Shaw Chin

Clinical Cardiology and Cardiovascular Interventions, we deeply appreciate the interest shown in our work and its publication. It has been a true pleasure to collaborate with you. The peer review process, as well as the support provided by the editorial office, have been exceptional, and the quality of the journal is very high, which was a determining factor in our decision to publish with you.

img

Gomez Barriga Maria Dolores

Clinical Cardiology and Cardiovascular Interventions I testity the covering of the peer review process, support from the editorial office, and quality of the journal.

img

Khurram Arshad

Dear editorial department: On behalf of our team, I hereby certify the reliability and superiority of the International Journal of Clinical Case Reports and Reviews in the peer review process, editorial support, and journal quality. Firstly, the peer review process of the International Journal of Clinical Case Reports and Reviews is rigorous, fair, transparent, fast, and of high quality. The editorial department invites experts from relevant fields as anonymous reviewers to review all submitted manuscripts. These experts have rich academic backgrounds and experience, and can accurately evaluate the academic quality, originality, and suitability of manuscripts. The editorial department is committed to ensuring the rigor of the peer review process, while also making every effort to ensure a fast review cycle to meet the needs of authors and the academic community. Secondly, the editorial team of the International Journal of Clinical Case Reports and Reviews is composed of a group of senior scholars and professionals with rich experience and professional knowledge in related fields. The editorial department is committed to assisting authors in improving their manuscripts, ensuring their academic accuracy, clarity, and completeness. Editors actively collaborate with authors, providing useful suggestions and feedback to promote the improvement and development of the manuscript. We believe that the support of the editorial department is one of the key factors in ensuring the quality of the journal. Finally, the International Journal of Clinical Case Reports and Reviews is renowned for its high- quality articles and strict academic standards. The editorial department is committed to publishing innovative and academically valuable research results to promote the development and progress of related fields. The International Journal of Clinical Case Reports and Reviews is reasonably priced and ensures excellent service and quality ratio, allowing authors to obtain high-level academic publishing opportunities in an affordable manner. I hereby solemnly declare that the International Journal of Clinical Case Reports and Reviews has a high level of credibility and superiority in terms of peer review process, editorial support, reasonable fees, and journal quality. Sincerely, Rui Tao.

img

Rui Tao

“The peer review process of JPMHC is quick and effective. Authors are benefited by good and professional reviewers with huge experience in the field of psychology and mental health. The support from the editorial office is very professional. People to contact to are friendly and happy to help and assist any query authors might have. Quality of the Journal is scientific and publishes ground-breaking research on mental health that is useful for other professionals in the field”.

img

George Varvatsoulias

Dr.Tania Muñoz, My experience as researcher and author of a review article in The Journal Clinical Cardiology and Interventions has been very enriching and stimulating. The editorial team is excellent, performs its work with absolute responsibility and delivery. They are proactive, dynamic and receptive to all proposals. Supporting at all times the vast universe of authors who choose them as an option for publication. The team of review specialists, members of the editorial board, are brilliant professionals, with remarkable performance in medical research and scientific methodology. Together they form a frontline team that consolidates the JCCI as a magnificent option for the publication and review of high-level medical articles and broad collective interest. I am honored to be able to share my review article and open to receive all your comments.

img

Tania Munoz

I am delighted to publish our manuscript entitled "A Perspective on Cocaine Induced Stroke - Its Mechanisms and Management" in the Journal of Neuroscience and Neurological Surgery. The peer review process, support from the editorial office, and quality of the journal are excellent. The manuscripts published are of high quality and of excellent scientific value. I recommend this journal very much to colleagues.

img

S Munshi

I would like to give my testimony in the support I have got by the peer review process and to support the editorial office where they were of asset to support young author like me to be encouraged to publish their work in your respected journal and globalize and share knowledge across the globe. I really give my great gratitude to your journal and the peer review including the editorial office.

img

Husain Taha Radhi

I am very pleased to serve as EBM of the journal, I hope many years of my experience in stem cells can help the journal from one way or another. As we know, stem cells hold great potential for regenerative medicine, which are mostly used to promote the repair response of diseased, dysfunctional or injured tissue using stem cells or their derivatives. I think Stem Cell Research and Therapeutics International is a great platform to publish and share the understanding towards the biology and translational or clinical application of stem cells.

img

Dr Tong Ming Liu

We are grateful for this opportunity to provide a glowing recommendation to the Journal of Psychiatry and Psychotherapy. We found that the editorial team were very supportive, helpful, kept us abreast of timelines and over all very professional in nature. The peer review process was rigorous, efficient and constructive that really enhanced our article submission. The experience with this journal remains one of our best ever and we look forward to providing future submissions in the near future.

img

Dr Griffith

I would like to express my gratitude towards you process of article review and submission. I found this to be very fair and expedient. Your follow up has been excellent. I have many publications in national and international journal and your process has been one of the best so far. Keep up the great work.

img

Douglas Miyazaki

"We recently published an article entitled “Influence of beta-Cyclodextrins upon the Degradation of Carbofuran Derivatives under Alkaline Conditions" in the Journal of “Pesticides and Biofertilizers” to show that the cyclodextrins protect the carbamates increasing their half-life time in the presence of basic conditions This will be very helpful to understand carbofuran behaviour in the analytical, agro-environmental and food areas. We greatly appreciated the interaction with the editor and the editorial team; we were particularly well accompanied during the course of the revision process, since all various steps towards publication were short and without delay".

img

Jesus Simal-Gandara

I am very glad to say that the peer review process is very successful and fast and support from the Editorial Office. Therefore, I would like to continue our scientific relationship for a long time. And I especially thank you for your kindly attention towards my article. Have a good day!

img

Baheci Selen

Dear Erica Kelsey, Editorial Coordinator of Cancer Research and Cellular Therapeutics Our team is very satisfied with the processing of our paper by your journal. That was fast, efficient, rigorous, but without unnecessary complications. We appreciated the very short time between the submission of the paper and its publication on line on your site.

img

Bruno Chauffert

Thank you very much for publishing my Research Article titled “Comparing Treatment Outcome Of Allergic Rhinitis Patients After Using Fluticasone Nasal Spray And Nasal Douching" in the Journal of Clinical Otorhinolaryngology. As Medical Professionals we are immensely benefited from study of various informative Articles and Papers published in this high quality Journal. I look forward to enriching my knowledge by regular study of the Journal and contribute my future work in the field of ENT through the Journal for use by the medical fraternity. The support from the Editorial office was excellent and very prompt. I also welcome the comments received from the readers of my Research Article.

img

Dr Suramya Dhamija

International Journal of Clinical Case Reports and Reviews. I strongly recommend to consider submitting your work to this high-quality journal. The support and availability of the Editorial staff is outstanding and the review process was both efficient and rigorous.

img

Andreas Filippaios

Dear Agrippa Hilda, Journal of Neuroscience and Neurological Surgery, Editorial Coordinator, I trust this message finds you well. I want to extend my appreciation for considering my article for publication in your esteemed journal. I am pleased to provide a testimonial regarding the peer review process and the support received from your editorial office. The peer review process for my paper was carried out in a highly professional and thorough manner. The feedback and comments provided by the authors were constructive and very useful in improving the quality of the manuscript. This rigorous assessment process undoubtedly contributes to the high standards maintained by your journal.

img

Raed Mualem

As an author who has recently published in the journal "Brain and Neurological Disorders". I am delighted to provide a testimonial on the peer review process, editorial office support, and the overall quality of the journal. The peer review process at Brain and Neurological Disorders is rigorous and meticulous, ensuring that only high-quality, evidence-based research is published. The reviewers are experts in their fields, and their comments and suggestions were constructive and helped improve the quality of my manuscript. The review process was timely and efficient, with clear communication from the editorial office at each stage. The support from the editorial office was exceptional throughout the entire process. The editorial staff was responsive, professional, and always willing to help. They provided valuable guidance on formatting, structure, and ethical considerations, making the submission process seamless. Moreover, they kept me informed about the status of my manuscript and provided timely updates, which made the process less stressful. The journal Brain and Neurological Disorders is of the highest quality, with a strong focus on publishing cutting-edge research in the field of neurology. The articles published in this journal are well-researched, rigorously peer-reviewed, and written by experts in the field. The journal maintains high standards, ensuring that readers are provided with the most up-to-date and reliable information on brain and neurological disorders. In conclusion, I had a wonderful experience publishing in Brain and Neurological Disorders. The peer review process was thorough, the editorial office provided exceptional support, and the journal's quality is second to none. I would highly recommend this journal to any researcher working in the field of neurology and brain disorders.

img

Dr Shiming Tang

Dear Hao Jiang, to Journal of Nutrition and Food Processing We greatly appreciate the efficient, professional and rapid processing of our paper by your team. If there is anything else we should do, please do not hesitate to let us know. On behalf of my co-authors, we would like to express our great appreciation to editor and reviewers.

img

Hao Jiang

This is an acknowledgment for peer reviewers, editorial board of Journal of Clinical Research and Reports. They show a lot of consideration for us as publishers for our research article “Evaluation of the different factors associated with side effects of COVID-19 vaccination on medical students, Mutah university, Al-Karak, Jordan”, in a very professional and easy way. This journal is one of outstanding medical journal.

img

Prof Sherif W Mansour

Dr. Bernard Terkimbi Utoo, I am happy to publish my scientific work in Journal of Women Health Care and Issues (JWHCI). The manuscript submission was seamless and peer review process was top notch. I was amazed that 4 reviewers worked on the manuscript which made it a highly technical, standard and excellent quality paper. I appreciate the format and consideration for the APC as well as the speed of publication. It is my pleasure to continue with this scientific relationship with the esteem JWHCI.

img

Bernard Terkimbi Utoo

Testimony of Journal of Clinical Otorhinolaryngology: work with your Reviews has been a educational and constructive experience. The editorial office were very helpful and supportive. It was a pleasure to contribute to your Journal.

img

Pedro Marques Gomes

Thank you most sincerely, with regard to the support you have given in relation to the reviewing process and the processing of my article entitled "Large Cell Neuroendocrine Carcinoma of The Prostate Gland: A Review and Update" for publication in your esteemed Journal, Journal of Cancer Research and Cellular Therapeutics". The editorial team has been very supportive.

img

Anthony Kodzo-Grey Venyo

Dr. Katarzyna Byczkowska My testimonial covering: "The peer review process is quick and effective. The support from the editorial office is very professional and friendly. Quality of the Clinical Cardiology and Cardiovascular Interventions is scientific and publishes ground-breaking research on cardiology that is useful for other professionals in the field.

img

Katarzyna Byczkowska

Journal of Neuroscience and Neurological Surgery. I had the experience of publishing a research article recently. The whole process was simple from submission to publication. The reviewers made specific and valuable recommendations and corrections that improved the quality of my publication. I strongly recommend this Journal.

img

Orlando Villarreal

The peer-review process which consisted high quality queries on the paper. I did answer six reviewers’ questions and comments before the paper was accepted. The support from the editorial office is excellent.

img

Sing-yung Wu

We would like to thank the Journal of Thoracic Disease and Cardiothoracic Surgery because of the services they provided us for our articles. The peer-review process was done in a very excellent time manner, and the opinions of the reviewers helped us to improve our manuscript further. The editorial office had an outstanding correspondence with us and guided us in many ways. During a hard time of the pandemic that is affecting every one of us tremendously, the editorial office helped us make everything easier for publishing scientific work. Hope for a more scientific relationship with your Journal.

img

Layla Shojaie

Journal of Clinical Research and Reports I would be very delighted to submit my testimonial regarding the reviewer board and the editorial office. The reviewer board were accurate and helpful regarding any modifications for my manuscript. And the editorial office were very helpful and supportive in contacting and monitoring with any update and offering help. It was my pleasure to contribute with your promising Journal and I am looking forward for more collaboration.

img

Mina Sherif Soliman Georgy

Journal of Women Health Care and Issues By the present mail, I want to say thank to you and tour colleagues for facilitating my published article. Specially thank you for the peer review process, support from the editorial office. I appreciate positively the quality of your journal.

img

Ziemlé Clément Méda

Journal of Clinical Cardiology and Cardiovascular Intervention The submission and review process was adequate. However I think that the publication total value should have been enlightened in early fases. Thank you for all.

img

Delcio G Silva Junior

Clearly Auctoresonline and particularly Psychology and Mental Health Care Journal is dedicated to improving health care services for individuals and populations. The editorial boards' ability to efficiently recognize and share the global importance of health literacy with a variety of stakeholders. Auctoresonline publishing platform can be used to facilitate of optimal client-based services and should be added to health care professionals' repertoire of evidence-based health care resources.

img

Virginia E. Koenig